Effect of Statin Therapy on Cardiovascular Events in High-Risk Group Identified by a Coronary Artery Calcium-Trained Deep Learning Model Using Retinal Imaging: A Propensity Score-Matched Study from the UK Biobank
Abstract Body (Do not enter title and authors here): Introduction: Cardiovascular disease (CVD) remains the leading cause of mortality globally, necessitating improved risk stratification and preventive strategies. Reti-CVD, a deep learning model, predicts CVD risk by analyzing retinal images to detect subtle vascular changes indicative of coronary artery calcium presence. This study evaluates the efficacy of statin therapy in individuals identified as high-risk by Reti-CVD using propensity score matching and survival analysis.
Hypothesis: Individuals with high Reti-CVD scores will benefit significantly from statin therapy, resulting in a reduced incidence of cardiovascular events compared to those not receiving statins.
Methods: Data from the UK Biobank were utilized to perform 1:1 propensity score matching, comparing statin users and non-users. Matching was based on age, gender, race, BMI, systolic blood pressure, diastolic blood pressure, medication use for blood pressure, diabetes status, smoking status, alcohol consumption, and socioeconomic status. Within a cohort identified as high-risk by a deep learning model, survival analysis of a mean follow-up period of 9.83 years for CVD outcomes was conducted, with the hazard ratio calculated for statin users versus non-users.
Results: In the unmatched cohort, significant differences were observed in several variables including age and gender between statin users (n=3,008) and non-users (n=42,373) as shown in Table 1. Post-matching, the cohort comprised 3,008 statin users and 3,008 non-users, with standardized mean differences significantly reduced for most variables. For the high Reti-CVD cohort, the hazard ratio for CVD outcomes in the statin group was 0.76 (95% CI: 0.50-1.14), indicating a 24% reduction in the risk of cardiovascular events compared to non-users. In comparison, the low to medium Reti-CVD cohort had a hazard ratio of 1.22 (95% CI: 0.90-1.68).
Discussion: Findings suggest that individuals with high Reti-CVD scores likely benefit from statin therapy, as indicated by a trend towards reduced cardiovascular events. Reti-CVD shows potential in refining risk stratification for guiding statin therapy decisions. The integration of deep learning models like Reti-CVD in clinical practice could provide targeted interventions for high-risk populations.
Cho, Yunnie
( Seoul National University Hospital
, Seoul
, Korea (the Republic of)
)
Cheng, Ching Yu
( Singapore National Eye Centre
, Singapore
, Singapore
)
Rim, Tyler
( Mediwhale Inc.
, Seoul
, Korea (the Republic of)
)
Lee, Chan Joo
( Severance Cardiovascular Hospital
, Seoul
, Korea (the Republic of)
)
Park, Sung Ha
( Severance Cardiovascular Hospital
, Seoul
, Korea (the Republic of)
)
Kim, Hyeonmin
( Pohang University of Science and Technology(POSTECH)
, Pohang
, Korea (the Republic of)
)
Seo, Chanyang
( Mediwhale Inc.
, Seoul
, Korea (the Republic of)
)
Yu, Marco
( Singapore National Eye Centre
, Singapore
, Singapore
)
Thakur, Sahil
( Singapore National Eye Centre
, Singapore
, Singapore
)
Wong, Tien
( Singapore National Eye Centre
, Singapore
, Singapore
)
Author Disclosures:
Yunnie Cho:DO have relevant financial relationships
;
Researcher:Mediwhale:Active (exists now)
| Ching Yu Cheng:No Answer
| Tyler Rim:DO have relevant financial relationships
;
Employee:Mediwhale:Active (exists now)
; Individual Stocks/Stock Options:Mediwhale:Active (exists now)
; Ownership Interest:Mediwhale:Active (exists now)
| Chan Joo Lee:DO have relevant financial relationships
;
Speaker:Norvatis:Past (completed)
; Individual Stocks/Stock Options:Mediwhale:Active (exists now)
; Speaker:Daiichi Sankyu:Past (completed)
; Speaker:Boryung Pharmaceutical:Past (completed)
; Speaker:Yuhan:Past (completed)
; Speaker:Hanmi Pharmaceutical:Past (completed)
| Sung Ha Park:DO have relevant financial relationships
;
Individual Stocks/Stock Options:Mediwhale:Active (exists now)
; Consultant:Skylab:Past (completed)
; Speaker:Donga:Past (completed)
; Speaker:Daewoong:Past (completed)
; Speaker:Viatris:Past (completed)
; Speaker:Organon:Past (completed)
; Research Funding (PI or named investigator):Sankyo:Active (exists now)
; Speaker:Boryung:Past (completed)
| Hyeonmin Kim:No Answer
| Chanyang Seo:No Answer
| Marco Yu:No Answer
| Sahil Thakur:No Answer
| Tien Wong:DO have relevant financial relationships
;
Consultant:Abbvie Pte Ltd:Past (completed)
; Other (please indicate in the box next to the company name):EyRIS (Co-founder):Active (exists now)
; Consultant:Shanghai Henlius:Active (exists now)
; Consultant:Sanofi:Past (completed)
; Consultant:Roche:Active (exists now)
; Consultant:Plano:Active (exists now)
; Consultant:Quaerite Biopharm Research Ltd:Active (exists now)
; Consultant:Opthea Limited:Active (exists now)
; Consultant:Novartis:Past (completed)
; Consultant:Iveric Bio:Past (completed)
; Other (please indicate in the box next to the company name):VISRE (Co-founder):Active (exists now)
; Consultant:Carl Zeiss:Active (exists now)
; Consultant:Boehringer Ingelheim:Active (exists now)
; Consultant:Bayer:Active (exists now)
; Consultant:Aldropika Therapeutics :Active (exists now)
Cho Jungkyung, Lee Chan Joo, Chun Kyeong-hyeon, Park Sung Ha, Park Junseok, Nam Dongjin, Thakur Sahil, Rukmini A.v., Park Tae Hyun, Seo Jaewon, Nusinovici Simon, Rim Tyler Hyungtaek
Cho Yunnie, Tan Yong Yu, Wong Tien, Cheng Ching-yu, Generoso Giuliano, Correa Fabiano Ronaldo, Bensenor Isabela, Bittencourt Marcio, Cho Jun Hwan, Rim Tyler, Choi Beom-hee, Jung Gyouchul, Lee Chan Joo, Park Sung Ha, Kim Hyeonmin, Seo Chanyang, Thakur Sahil
4140651_File000000.jpg
You have to be authorized to contact abstract author. Please, Login